FDA Announces Model-Informed Drug Development Approaches Program Under PDUFA VII

Summary

The FDA is continuing the Model-Informed Drug Development (MIDD) Paired Meeting Program to advance model-informed drug development approaches in medical product development, as part of the Prescription Drug User Fee Act of 2023 (PDUFA VII) and the FDA User Fee Reauthorization Act of 2022.